Coronavirus disease-2019 and the intestinal tract : An overview
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved..
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can progress to a severe respiratory and systemic disease named coronavirus disease-2019 (COVID-19). The most common symptoms are fever and respiratory discomfort. Nevertheless, gastrointestinal infections have been reported, with symptoms such as diarrhea, nausea, vomiting, abdominal pain, and lack of appetite. Importantly, SARS-CoV-2 can remain positive in fecal samples after nasopharyngeal clearance. After gastrointestinal SARS-CoV-2 infection and other viral gastrointestinal infections, some patients may develop alterations in the gastrointestinal microbiota. In addition, some COVID-19 patients may receive antibiotics, which may also disturb gastrointestinal homeostasis. In summary, the gastrointestinal system, gut microbiome, and gut-lung axis may represent an important role in the development, severity, and treatment of COVID-19. Therefore, in this review, we explore the current pieces of evidence of COVID-19 gastrointestinal manifestations, possible implications, and interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
World journal of gastroenterology - 27(2021), 13 vom: 07. Apr., Seite 1255-1266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alberca, Gabriela Gama Freire [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotics |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 06.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3748/wjg.v27.i13.1255 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323886302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323886302 | ||
| 003 | DE-627 | ||
| 005 | 20231225185135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3748/wjg.v27.i13.1255 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323886302 | ||
| 035 | |a (NLM)33833480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alberca, Gabriela Gama Freire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coronavirus disease-2019 and the intestinal tract |b An overview |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 06.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can progress to a severe respiratory and systemic disease named coronavirus disease-2019 (COVID-19). The most common symptoms are fever and respiratory discomfort. Nevertheless, gastrointestinal infections have been reported, with symptoms such as diarrhea, nausea, vomiting, abdominal pain, and lack of appetite. Importantly, SARS-CoV-2 can remain positive in fecal samples after nasopharyngeal clearance. After gastrointestinal SARS-CoV-2 infection and other viral gastrointestinal infections, some patients may develop alterations in the gastrointestinal microbiota. In addition, some COVID-19 patients may receive antibiotics, which may also disturb gastrointestinal homeostasis. In summary, the gastrointestinal system, gut microbiome, and gut-lung axis may represent an important role in the development, severity, and treatment of COVID-19. Therefore, in this review, we explore the current pieces of evidence of COVID-19 gastrointestinal manifestations, possible implications, and interventions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibiotics | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Gastrointestinal | |
| 650 | 4 | |a Microbiota | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Solis-Castro, Rosa Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Solis-Castro, Maria Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Alberca, Ricardo Wesley |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastroenterology |d 1997 |g 27(2021), 13 vom: 07. Apr., Seite 1255-1266 |w (DE-627)NLM117065250 |x 2219-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:13 |g day:07 |g month:04 |g pages:1255-1266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3748/wjg.v27.i13.1255 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 13 |b 07 |c 04 |h 1255-1266 | ||